PDGF-B-driven gliomagenesis can occur in the absence of the proteoglycan NG2

BACKGROUND: In the last years, the transmembrane proteoglycan NG2 has gained interest as a therapeutic target for the treatment of diverse tumor types, including gliomas, because increases of its expression correlate with dismal prognosis. NG2 has been shown to function as a co-receptor for PDGF lig...

Descripción completa

Detalles Bibliográficos
Autores principales: Terrile, Marta, Appolloni, Irene, Calzolari, Filippo, Perris, Roberto, Tutucci, Evelina, Malatesta, Paolo
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2964636/
https://www.ncbi.nlm.nih.gov/pubmed/20939912
http://dx.doi.org/10.1186/1471-2407-10-550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2964636/
https://www.ncbi.nlm.nih.gov/pubmed/20939912
http://dx.doi.org/10.1186/1471-2407-10-550

Ejemplares similares